Methods: From 1992 to 2012 in a retrospective study from our center pediatric patients (age <15) with acute myelobalstic leukemia (AML) and ALL candidate for HSCT included. The patients were prepared using a non-radiation-based conditioning regimen (busulfan/cyclophosphamide in allogenic and busulfan/etoposide in autologus). In the allogenic HSCT, Cyclosporine A and methotrexate were used as graft-versus-host disease (GvHD) prophylaxis regimen.
Results: Of 268 patients with AML (autologus=57, allogenic=104) and ALL (allogenic=107), 137(51%) of them were boys and 131(49%) were girls. The median age at transplantation were 11years (range: 1-15years) in AML patients and 12years (range: 0.8-15years) in ALL patients. With a median follow up of 31 months for AML patients, overall survival (OS), disease free survival (DFS) for autologus and allogenic transplantations were 64%, 59.2% and 69%,61.5% respectively. In ALL patients with a median follow up of 14 months, OS and DFS were 80.3% and 70%. The most common cause of deaths in both AML and ALL patients was relapse (63% and 71%). Regarding GVHD occurrence, in AML and ALL patients 67 (41.6%) and 61 (57%) did experience acute GVHD. Considering chronic GVHD for AML and ALL patients, results were 20(12.4%) and 13(12.1%).
Conclusion: Regarding the adverse effects of using TBI-based conditioning regimen, it seems that in pediatric patients with AML and ALL using a non-TBI based conditioning regimen can be a good alternative in HSCT. However, large controlled well-designed studies are needed for further understanding of differences between TBI and non-TBI conditioning regimens.